CpG 1018/Alum-adjuvanted SCB-2019 vaccine

BIOLOGICAL2 trials

Sponsors

Clover Biopharmaceuticals AUS Pty

Conditions

COVID-19

Phase 2

A Controlled Phase 2/3 Study of Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Vaccine (SCB-2019) for the Prevention of COVID-19

CompletedNCT04672395

Clover Biopharmaceuticals AUS PtyCOVID-19

Start: 2021-03-24End: 2023-04-23Updated: 2023-06-29

Phase 3

Safety and Immunogenicity of Adjuvanted SARS-CoV-2 (SCB-2019) Vaccine in Adults With Chronic Immune-Mediated Diseases

TerminatedNCT05012787

Clover Biopharmaceuticals AUS PtyCOVID-19

Start: 2021-11-12End: 2022-05-04Updated: 2023-03-24

Related Papers

Indirect effectiveness of a novel SARS-COV-2 vaccine (SCB-2019) in unvaccinated household contacts in the Philippines: A cluster randomised analysis.

2024-08-301 citations

Six-month safety follow-up of an adjuvanted SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019) in adults: A phase 2/3, double-blind, randomized study.

2023-02-104 citations

Immunogenicity of an adjuvanted SARS-CoV-2 trimeric S-protein subunit vaccine (SCB-2019) in SARS-CoV-2-naïve and exposed individuals in a phase 2/3, double-blind, randomized study.

2023-02-099 citations

Safety and immunogenicity of SCB-2019, an adjuvanted, recombinant SARS-CoV-2 trimeric S-protein subunit COVID-19 vaccine in healthy 12–17 year-old adolescents

Human Vaccines & Immunotherapeutics2023-01-026 citations

Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial.

2022-01-2087 citations